Both in Pharmaceuticals
Kura Oncology vs Design Therapeutics
Over the past year KURA returned −16.8% and DSGN returned +60.9%; their daily moves had a correlation of 0.31.
KURA −16.8% DSGN +60.9%Growth of $1, one year, split-adjusted
| Metric | KURA | DSGN |
|---|---|---|
| Price | $8.13 | $10.54 |
| Market cap | $723.2M | $659.6M |
| Today | −17.71% | +1.93% |
| 1 month | −22.8% | −11.9% |
| 6 months | −15.0% | −27.6% |
| Year to date | −21.8% | +12.4% |
| 1 year | −16.8% | +60.9% |
| Revenue growth (YoY) | +36.5% | — |
| Gross margin | 98.8% | — |
| Net margin | −327.3% | — |
| P/E (TTM) | — | — |
| Price / sales | 9.4× | — |
| Net cash | $509.2M | $207.4M |
| Dividend yield | — | — |
| Volatility (60d) | 68.4% | 55.2% |
| Short % of float | 18.3% | 21.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).